My watch list  

32 Current news of Ascenion


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
CARMA FUND I Completes First Closing of EUR 47 Million to Accelerate the Transfer of Life-Science Research into Practice


Aconsortium of strong partners has launched the CARMA FUND I as a new vehicle for the translation of promising early-stage life-science projects: the initiators, Ascenion GmbH, a life-science focused technology transfer company of the LifeScience Foundation and the Goethe-University, Frankfurt ...


image description
BioVaria Startup Pitch & Partner Awards go to Exactmer and Lymphatica Medtech


This year’s hybrid BioVaria brought together over 230 life-science innovators – most of them live in Munich – boosting academia–industry partnering. Following two years of mainly virtual interaction, the event was well received by investors and decision makers from industry as well as academic ...


image description
Cardior Raises EUR 64 Million to Develop RNA Therapeutics Against Cardiac Disease

Start-up pursues a unique approach for the treatment


Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMed Partners, ...


image description
Ascenion’s portfolio company T-knife receives $110 million for the development of innovative T-cell therapies in cancer

Initiation of the IMAGE1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in Q4 2021


T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with ...


image description
BioVaria Startup Awards go to iRASP Therapeutics and OrganoTherapeutics

New platform for developing therapeutic antibodies against cancer and new approach to the development of drugs for Parkinson’s disease


This year’s virtual BioVaria from 26 to 28 April brought together 250 life-science innovators to hear about the most exciting technologies and start-ups to emerge from publicly funded European research, and to initiate partnerships between science and business. With 75 licensable projects and 16 ...


image description
Spin-off from Charité want to advance AI-powered pathology

Aignostics Raises €5 Million Seed Round


Aignostics, a spin-off from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) pioneering computational pathology for pharmaceutical research and diagnostics, has announced the closing of a €5 M seed round funding. Boehringer Ingelheim Venture Fund (BIVF) led the round, ...


image description
T-knife Completes €66 Million Series A Financing to Develop Next Generation T-Cell Therapies

T-knife’s proprietary humanized mouse platform (HuTCR) T-cell Receptors expected to provide superior affinity/specificity properties


T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, announced the closing of a €66 M Series A round of financing. The round was led by Versant Ventures and RA Capital Management, with significant ...


New drug delivery system to enable needle-free application of drugs

Ascenion's Portfolio Company WBC Acquired by Klaria


Ascenion GmbH, technology transfer partner of the Helmholtz Centre for Infection Research (HZI), announces the take-over of its portfolio company WBC Drug Delivery Technologies (WBC) by Klaria Pharma Holding AB in an all-stock deal. WBC was founded earlier this year to further advance a new drug ...


BioVaria Start-up Awards go to ISD Immunotech and


The 12th BioVaria welcomed over 250 life-science innovators to Munich, including biopharma executives, investors, academic inventors, entrepreneurs and technology transfer experts. There were 67 peer-selected licensing opportunities on offer, originating from as many research institutes, ...


Canopy Biosciences Acquires Zellkraftwerk GmbH


Canopy Biosciences, LLC, a leading provider of gene editing and gene expression products and services, announced today that it has acquired Zellkraftwerk GmbH, a leader in multiplex cytometry and a spinoff of Hannover Medical School founded by Dr Christian Hennig, Dr Jan Detmers and Ascenion. ...


Page 1 From 4
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE